Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20217229 | 0.73 | CTSS (0.33) | CTSSC3AR1 | |
| SCHEMBL16310058 | 0.73 | CTSS (0.33) | CTSSC3AR1 | |
| SCHEMBL6807685 | 0.72 | NPC1 (0.41) | NPC1RAB9AITGB3ITGB1ITGAV | |
| SCHEMBL9087858 | 0.72 | RAB9A (0.50) | NPC1RAB9AITGB3ITGB1ITGAV | |
| SCHEMBL7181514 | 0.72 | RAB9A (0.50) | NPC1RAB9AITGB3ITGB1ITGAV | |
| SCHEMBL6802479 | 0.71 | CTSS (0.43) | CTSSNPC1RAB9AACHEBACE1 | |
| SCHEMBL6803515 | 0.70 | ITGB3 (0.39) | CTSSNPC1RAB9AITGB3ITGB1 | |
| SCHEMBL6804384 | 0.68 | CTSS (0.41) | CTSSNPC1RAB9AITGB3ITGB1 | |
| SCHEMBL15550386 | 0.68 | IDO1 (0.44) | C3AR1HRH3 | |
| SCHEMBL6802536 | 0.67 | NPC1 (0.41) | NPC1RAB9AITGB3ITGB1ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | CTSS 1081/4885NPC1 2721/4885RAB9A 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.